Lazard Global Thematic Equity Performance (Gross of fees; through 31 January 2014) Performance reported gross of fees. Past performance is not necessarily indicative of future performance. Benchmark returns MSCI net official numbers. Source: MSCI. Based on a representative account. Commentary Market Overview Equity markets swooned in January. The emerging markets fell most as capital
sydneyrx2014.com Online ED Pharmacy is an 1st. pharmacy providing a personal service to the community in Australia. Over 50,000 extremely satisfied customers! We're your prescription drug store cialis australia and have provided trusted service to families in Australia for over 15 years.
The "Arterium" Corporation
01032, Kiev, Saksaganskogo Street, 139
Tel: (+380 44) 490 75 22
Fax: (+380 44) 490 75 17
Chief Executive Officer: Dennis Gartsylov
The "Arterium" Corporation - one of the leading Ukrainian pharmaceutical
companies, which operates in the industry that cares about the most important
values - health and preservation of human life.
Established in 2005, the "Arterium" Corporation brings together two Ukrainian
companies with more than a century and a half tradition of medicine manufacturing:
JSC "Kyivmedpreparat" - the largest Ukrainian producer of antibacterial drugs and
JSC "Halychpharm" - leader in production of plant-based medications.
The Ukrainian market is the essential one for the entire Corporation’s activity. At the
same time to ensure marketing activities on the external markets the Corporation
has opened its representative offices in CIS countries such as: Russia, Belarus,
Kazakhstan and Uzbekistan.
A key focus of the "Arterium" Corporation is the production, marketing and
distribution of modern, efficient, safe and high quality medicines to ensure a long
and productive life. Currently we manufacture over 140 generic and several original
drugs in 10 of 14 ATC groups. In the range of the Corporation products there are a
number of original medicines: Thiotriazolin®, L-lysine aescinat®, Tiocetam® and
Urolesan®. All of them have received the recognition and trust of the medical
community because of their efficiency and proven quality.
We pay close attention to the needs of patients, health care system and produce the
modern generic drugs which have proved to the world medical and clinical practice.
Thanks to affordable price and high quality, which have been confirmed by the
certification of production, our drugs will make it possible to raise to a higher level
the quality of treatment of a wider patients range making it closer to international
high standards. We are also constantly exploring therapeutic needs and direct our
efforts to find and develop original products, convenient to administrate
combinations of known substances, as well as new plant – based drugs. For the
period of 2009 -2011 there have been issued more than 40 new drugs (including
forms and dosages). For the period of 2012-2014 we are planning to release about
90 new medicines. All products issued by the Corporation in recent years have
undergone a number of required studies to comply with European quality standards
and have proven their efficiency. Since 2007, the Corporation has been regularly
conducting clinical trials of their drugs. The trials are aimed at proving the
equivalence of generic drugs produced by the Corporation versus more expensive
original drugs through bioequivalence studies and therapeutic equivalence. We keep
making all required preclinical and clinical studies having got our traditional as well
as new and original drugs in the Corporation’s product portfolio. These studies
provide the evidence base indicating the efficacy and safety of our products. All trials
are conducted in accordance with national and European legislation, as well as
mandatory compliance with the ethical principles of clinical trials.
Along with the manufacturing, marketing and distribution of traditional medicines,
the Corporation has started manufacturing and marketing of recombinant
(genetically engineered) medicines.
According to the 2010 sales results in Ukraine the Corporation has demonstrated
leadership in the antibiotic group and dermatological medicines, and also has taken a
leadership position in the group of medicines for the treatment of cardio - vascular
and nervous systems.
The leaders of sales in their target segments are:
Thiotriazolin ® - for the treatment of coronary heart disease
Amoxil ®, Azimed ®, Gepacef ® - antibiotics
Sonnat ® - treatments for sleep disorders
Tiocetam ® - medicines opposing the cerebrovascular disease
Diflyuzol ® - a group of antifungal drugs
Gerpevir ® - medicines opposing herpes.
The enterprises - members of the Corporation, operating under "ARTERIUM" brand
produce medicines known for their quality, both in Ukraine and abroad. Quality
management systems of the enterprises that are members of the "ARTERIUM"
corporation meet the international standard of environmental management DSTU
ISO 14001:2006. The production facilities of JSC "Kyivmedpreparat" and JSC
"Halychpharm" have been certified for compliance with Good Manufacturing Practice
We strive to establish harmonious, trusting and lasting relationships with all groups
and target audiences that are affected by our activities. In addition to output, which
rescues and helps to maintain human health and life, we recognize the importance of
social, regulatory and environmental issues and harmonious coexistence with all
organizations and individuals who interact with us. As a powerful Ukrainian
pharmaceutical manufacturer, we strive to bring as much benefit to our country, its
people and society as possible. The policy of corporate social responsibility initiative
includes the Corporation "ARTERIUM" - For a Healthy Lifestyle!" Programs of this
initiative include not only our staff but also doctors, pharmacists and consumers. As
business leaders, we aim to draw public attention to this issue and additionally we
are taking certain measures to increase the number of the healthy lifestyle initiative
JSC "Kyivmedpreparat" remains undisputable national leader in the production of
antibacterial drugs. The plant is one of the largest pharmaceutical industries in
Ukraine, as well as the most experienced venture of chemical and pharmaceutical
industry in the country with its creation falling into the middle of the XIX th century.
Today the plant produces about 100 generic and original medicines. Since 1847 the
company has been producing drugs in the following forms of production: injection in
vials, tablets, capsules, ointments, gels.
JSC "Halychpharm" has a unique experience in the field of phytochemical
production of finished drugs and extraction of vegetable substances for the
production of medicines. The history of this company has more than 100 years. Since
1911 the company produces medicines in the following forms: injections in
ampoules, tablets, solutions, extracts, syrups. The plant manufactures about 50
generic and original medicines.
Major languages: French, indigenous languages Major religions: Indigenous beliefs, Islam, Christianity Life expectancy: 47 years (men), 48 years (women) (UN) Monetary unit: 1 CFA (Communaute Financiere Africaine) franc = 100 centimes Main exports: Cotton, animal products, gold GNI per capita: US $400 (World Bank, 2006) Direction du Tourisme et de lHôtellerie BP 624, Ouagadougou 01, Bu